Breaking News, Collaborations & Alliances

Lonza Makes Bionomics Clinical Candidate

Manufactures cancer treatment materials at Slough

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza has begun manufacturing activities for Bionomics Limited‘s lead candidate, BNC101, following completion of key preclinical studies. BNC101 is a novel therapeutic antibody designed to target cancer stem cells. Eliminating cancer stem cells represents a new cancer treatment paradigm that could offer a distinct advantage over existing treatment strategies and a solution for resistance to chemotherapy. Bionomics plans to begin clinical trials in 2014. Lonza will manufacture BNC101 at its...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters